Skip to content

Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital

Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05002010
Enrollment
200
Registered
2021-08-12
Start date
2022-02-28
Completion date
2022-12-31
Last updated
2022-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Hypertrophy, Chronic Kidney Diseases

Brief summary

Assess the prevalence and features of left ventricular hypertrophy in patients with chronic kidney disease (CKD) taking into account gender differences and stage of CKD. To detect factors those predict LVH in CKD. \*to assess the right ventricle dysfunction in CKD .

Detailed description

The number of patients with chronic kidney disease (CKD) is growing worldwide, while patients with impaired renal function are at high or very high risk for developing cardiovascular disease (CVD). Mortality due to CVD in patients with CKD is 1020 times higher than that in the general population, and the likelihood of developing cardiovascular complications (CVC) is several times higher than the risk of end-stage CKD{1} In CKD cardiovascular disease abnormalities are due to volume overload, hypertension, endothelia dysfunction, inflammation, uremic pericarditis cardiomyopathy, anemia, dyslipidemia and oxidativel stress{2} Left ventricular hypertrophy (LVH) is a key feature that allows you to get an accurate picture of systolic-diastolic lesions of the left heart in patients with CKD and therefore is one of the most important factors in the development of adverse CVC LVH is initially formed as an adaptive process aimed at maintaining normal heart function under conditions of myocardial overload by pressure or volume, but then acquires the character of pathological adaptation, becoming the structural basis of heart failure, myocardial ischemia and cardiac arrhythmias {3}. It was shown that the probability of LVH increases already with a moderate decrease in eGFR and increases further as CKD progresses, reaching a maximum in the terminal stage \[4\]. . in CKD LVH is associated with increased mortality and the risk of adverse outcomes, especially at the terminal stage of CKD{5-6}

Interventions

DEVICEEcho

Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

\- Patients with chronic renal disease (CKD) aged between 16 and 65 years will be included. 2- CKD are diagnosed based on criteria proposed by KDIGO (Kidney Disease: Improving Global Outcomes) in 2002

Exclusion criteria

* Patients with structural heart disease (congenital or valvular heart disease). Patients with primary hypertension. Patients with obstructive or restrictive lung disease.

Design outcomes

Primary

MeasureTime frameDescription
Detecting the prevalence of LVH in CKD.through study completion, an average of 1 year.The types of LVH in different stages of CKD. Risk factors of LVH in different stages of CKD

Secondary

MeasureTime frame
The types of LVH in different stages of CKD. Risk factors of LVH in different stages of CKDthrough study completion, an average of 1 year.

Contacts

Primary ContactHeba Mohammed
Hebamohammed180@gmail.com01553466968
Backup ContactDina Ali
Dinaalihamad@aun.edu.eg+208822080150

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026